Eli Lilly and Company’s Donanemab FDA Decision Delay Eli Lilly and Company’s Donanemab FDA Decision Delay

Actionable Trade Ideas

always free

Lilly Stock Takes a Hit

Eli Lilly and Company’s (LLY) stock faced a 2.3% decline following the announcement of a delay in the FDA decision regarding its crucial pipeline candidate, donanemab.

Setback in Regulatory Filing

Lilly’s biologics license application (BLA) for donanemab was based on data from the TRAILBLAZER-ALZ 2 phase III study. An FDA advisory committee is now expected to convene to delve into the study data for more insights on donanemab’s safety and efficacy.

Market Response and Historical Performance

Originally slated for a first-quarter 2024 decision, the FDA’s postponement led to a drop in Lilly’s stock, which had surged an impressive 134.9% over the past year, outperforming the industry’s 34.0% increase.

Insights from the TRAILBLAZER-ALZ 2 Study

Data from the TRAILBLAZER-ALZ 2 trial showcased donanemab’s significant impact in slowing cognitive decline in patients with early symptomatic Alzheimer’s disease. Notably, a substantial proportion of patients saw no clinical progression compared to those on a placebo.

Comparative Landscape in Alzheimer’s Treatment

Amid the delay in donanemab’s FDA decision, attention shifts to other approved anti-amyloid beta therapies like Biogen’s Aduhelm and Eisai’s Leqembi. While the latter received full approval in the US, Aduhelm faced discontinuation after failing to gain traction in the market.

Investor Considerations and Analyst Rankings

With Lilly currently holding a Zacks Rank #3 (Hold), investors are eying potential future developments. Exploration of other healthcare stocks such as Vanda Pharmaceuticals (VNDA) and GSK, plc (GSK) may offer interesting opportunities, with both standing at a Zacks Rank #1 (Strong Buy).

Financial Projections and Performance Outlook

Analysts predict growth for both GSK and Vanda Pharmaceuticals, with improvements in earnings estimates. While GSK has seen a rise in stock value, Vanda Pharmaceuticals has experienced a recent decline despite delivering positive earnings surprises.

Expert Insights and Optimistic Predictions

As the market navigates through the implications of the FDA’s decision delay, analysts are eyeing potential opportunities for investors, highlighting certain stocks believed to have significant growth potential in the upcoming year.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.